# National Institutes of Health

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/national-institutes-of-health/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | US government medical research agency |
| OpenAlex ID | https://openalex.org/F4320332161 |
| ROR ID | https://ror.org/01cwqze88 |
| Works | 1,804,289 |

## Funder papers

Showing 15 of 229.

- [Development and Validation of the American Heart Association’s PREVENT Equations](https://scholariq.org/papers/development-and-validation-of-the-american-heart-association-s-prevent-equations/)
- [US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up](https://scholariq.org/papers/us-prevalence-of-self-reported-peanut-tree-nut-and-sesame-allergy-11-year-follow/)
- [Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/executive-summary-of-the-kdigo-2021-guideline-for-the-management-of-glomerular/)
- [The frequency and outcome of lupus nephritis: results from an international inception cohort study](https://scholariq.org/papers/the-frequency-and-outcome-of-lupus-nephritis-results-from-an-international/)
- [Podocytopathies](https://scholariq.org/papers/podocytopathies/)
- [Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes](https://scholariq.org/papers/concurrent-rb1-and-tp53-alterations-define-a-subset-of-egfr-mutant-lung-cancers/)
- [Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/patiromer-versus-placebo-to-enable-spironolactone-use-in-patients-with-resistant/)
- [Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups](https://scholariq.org/papers/canagliflozin-and-cardiovascular-and-renal-outcomes-in-type-2-diabetes-mellitus/)
- [Neural regions essential for distinct cognitive processes underlying picture naming](https://scholariq.org/papers/neural-regions-essential-for-distinct-cognitive-processes-underlying-picture/)
- [Exposure to Polyfluoroalkyl Chemicals and Attention Deficit/Hyperactivity Disorder in U.S. Children 12–15 Years of Age](https://scholariq.org/papers/exposure-to-polyfluoroalkyl-chemicals-and-attention-deficit-hyperactivity/)
- [Mindfulness-Based Stress Reduction for Family Caregivers: A Randomized Controlled Trial](https://scholariq.org/papers/mindfulness-based-stress-reduction-for-family-caregivers-a-randomized-controlled/)
- [Inhalation toxicity of acetaldehyde in rats. III. Carcinogenicity study](https://scholariq.org/papers/inhalation-toxicity-of-acetaldehyde-in-rats-iii-carcinogenicity-study/)
- [Serum Vaccine Antibody Concentrations in Adolescents Exposed to Perfluorinated Compounds](https://scholariq.org/papers/serum-vaccine-antibody-concentrations-in-adolescents-exposed-to-perfluorinated/)
- [A Practical Guide to the Therapy of Narcolepsy and Hypersomnia Syndromes](https://scholariq.org/papers/a-practical-guide-to-the-therapy-of-narcolepsy-and-hypersomnia-syndromes/)
- [Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial](https://scholariq.org/papers/long-term-kidney-outcomes-of-semaglutide-in-obesity-and-cardiovascular-disease/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.